Dexamethasone intratympanic - Otonomy

Drug Profile

Dexamethasone intratympanic - Otonomy

Alternative Names: OTO-104; Sustained release dexamethasone gel - Otonomy

Latest Information Update: 02 Nov 2016

Price : $50

At a glance

  • Originator Otonomy
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Meniere's disease
  • New Molecular Entity No

Highest Development Phases

  • Phase III Meniere's disease
  • Preclinical Sensorineural hearing loss

Most Recent Events

  • 29 Aug 2016 Phase-III clinical trials in Meniere's disease in Belgium (Intratympanic) (EudraCT2016-000766-29; 9193170)
  • 01 Aug 2016 Ontology initiates enrolment in a phase III trial for Meniere's Disease in USA (NCT02768662)
  • 01 Aug 2016 Adverse events data from a phase II trial in Meniere's disease released by Otonomy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top